Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
PHASE1CompletedINTERVENTIONAL
Timeline
Start Date
February 28, 2001
Conditions
Lymphoma
Interventions
BIOLOGICAL
aldesleukin
BIOLOGICAL
autologous tumor cell vaccine
Trial Locations (1)
20892
Medicine Branch, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00020462 - Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma | Biotech Hunter | Biotech Hunter